PMV Pharmaceuticals, Inc. — 2020 Form 10-K
Reporting period: Fiscal year ended December 31, 2020. This is an annual report, not a standalone fourth-quarter earnings report. Financial amounts below are in U.S. dollars; millions unless noted.
Business context and development
PMV is a clinical-stage precision oncology company developing small-molecule therapies intended to restore normal function to specific p53-mutant proteins. It has no approved products and has not generated revenue. Its lead candidate, PC14586, targets the p53 Y220C mutation, which the company estimates occurs in 1.0%–1.5% of cancers.
PMV began a Phase 1/2 trial of PC14586 in October 2020, dosed its first patient in the fourth quarter, and received FDA Fast Track designation. The filing reports no clinical results; efficacy claims are based on preclinical studies. Its R273H program was progressing toward lead optimization, while other programs remained in earlier research stages.
Financial performance and liquidity
| Metric | 2020 | 2019 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $23.9 | $20.8 |
| General and administrative expense | $11.0 | $5.9 |
| Total operating expenses / operating loss | $34.9 | $26.6 |
| Net loss | $34.4 | $25.4 |
| Net loss per share, basic and diluted | $2.40 | $8.35 |
| Cash used in operating activities | $32.7 | $22.1 |
Margins are not meaningful because PMV had no revenue. At December 31, 2020, cash and cash equivalents were $361.4 million; short-term marketable securities were zero. Working capital was $358.4 million, total current liabilities $6.4 million, and stockholders’ equity $359.1 million. The filing reports no debt balance. Management estimated available cash would fund planned operations at least through 2023, subject to assumptions and changing spending needs.
Cash from financing activities was $293.0 million, primarily reflecting $223.2 million of net IPO proceeds and $69.8 million of net Series D preferred-stock proceeds. Preferred shares converted to common stock at the IPO. Investing activities provided $27.9 million, mainly from security maturities.
Changes versus the prior year
- Net loss increased by $9.1 million; operating expenses rose $8.3 million. R&D increased $3.2 million as PC14586 advanced toward and into clinical testing, while G&A rose $5.1 million, reflecting increased staffing, public-company infrastructure, insurance and outside services.
- Operating cash use increased $10.7 million. Cash and cash equivalents rose from $73.3 million to $361.4 million, principally due to IPO and preferred-stock financing.
- Interest income declined $0.6 million to $0.7 million, primarily reflecting lower income on cash investments. The IPO and preferred-stock conversion substantially changed the company’s capital structure and share count.
Outlook, risks and unusual items
- Management expects significant losses and higher R&D spending as programs advance; it cannot predict when, or whether, PMV will generate product revenue or achieve profitability. It expects to rely on future equity or debt financing, collaborations, or other funding if needed.
- The accelerated-approval strategy and potential use of the Phase 1/2 study as a pivotal trial are not assured. The FDA may require additional trials; accelerated approval, if obtained, could require post-approval confirmation. Fast Track is not a guarantee of approval.
- Key risks include the unproven science and early development stage, dependence on PC14586, safety and clinical efficacy uncertainty, mutation-specific patient recruitment, companion-diagnostic development and approval, competition, patent protection, reimbursement, and reliance on contract research and manufacturing providers.
- COVID-19 could disrupt enrollment, clinical sites, laboratory work, supply chains and regulatory timelines. The company also identified reliance on certain China-based development or manufacturing activities as a potential supply and geopolitical risk.
- In January 2021, PMV signed a lease for a new Princeton office and laboratory facility through 2032, with stated payments of $19.6 million through May 2032; this commitment was subsequent to year-end and is not included in the $0.7 million of lease obligations reported at December 31, 2020.
- The financial statements received an unqualified audit opinion. Management concluded disclosure controls and internal control over financial reporting were effective at year-end; the auditor was not engaged to express an opinion on internal-control effectiveness.
Most important facts for investors to verify
- Clinical-trial progress, safety, dose selection and response data for PC14586, including whether results support the tumor-agnostic strategy.
- Cash burn, actual runway versus the stated through-2023 estimate, and any financing, collaboration or spending changes.
- FDA feedback on trial design, pivotal-study sufficiency, accelerated approval and any companion diagnostic requirements.
- Operational and financial effects of the new Princeton lease, clinical/manufacturing dependence on third parties, and China-related supply exposure.
- Potential dilution from outstanding options and equity plans, and the timing and effect of shares becoming eligible for resale after IPO lock-up periods.